Friday, 16 September 2016
BioPharma Conference Dublin - 21st Sept
Featuring international industry and research leaders from the medical and biopharma industries, the all island 2016 BioPharma Ambition Conference will take place on Wednesday 21 and Thursday 22 September in The National Institute for Bioprocessing Research and Training (NIBRT) in UCD, The Biomedical Sciences Institute (TBSI), Trinity College Dublin and the Printworks in Dublin Castle.
Sponsored by PwC, GE Healthcare, and United Drug (part of the McKesson Group), and Intertrade Ireland, the event will present the overall ambition of the biopharmaceutical industry, the challenges facing effective innovation, design and ultimately treatment. The event will also look at the role Ireland has to play in supporting research, discovery, development and manufacturing of healthcare solutions.
What: BioPharma Ambition Conference
When: Wednesday 21 September (NIBRT & TBSI) & Thursday 22 September (Plenary Session, Printworks, Dublin Castle)
Where: NIBRT UCD, Trinity Biomedical Sciences Institute (TBSI), The Mansion House, Printworks Dublin Castle
Media wishing to attend are invited to register in advance by emailing IPHA@humebrophy.com. Interview, photography and video recording opportunities will be available with speakers and representatives from the event organisers, Irish Pharmaceutical Healthcare Association (IPHA), BioPharmaChem Ireland (BPCI), the National Institute for Bioprocessing Research and Training (NIBRT) and Intertrade Ireland.
Minster for Health Simon Harris TD will address the Plenary Session at 13:15 on Thursday 22 September in the Printworks, Dublin Castle. The two-day event will also feature biopharma research and industry leaders such as:
· Michael Kopcha Director Office of Pharmaceutical Quality at the United States federal Food and Drug Administration
· Sir Andrew Dillion, Chief Executive, NICE UK
· Charles Cooney, FT Haslam Prof of Chemical Engineering, MIT
· Prof Luke O'Neill, Chair of Biochemistry, Trinity College Dublin
· Prof Garret FitzGerald, Director, Institute for Translational Medicine and Therapeutics, University of Pennsylvania